

# Agonistic Anti-4-1BB Antibody Promotes the Expansion of Natural Regulatory T Cells While Maintaining Foxp3 Expression

P. Zhang<sup>1</sup>, F. Gao<sup>1</sup>, Q. Wang, X. Wang, F. Zhu, C. Ma, W. Sun & L. Zhang

Institute of Immunology, Shandong University Medical School, Jinan, Shandong, China

Received 17 January 2007; Accepted in revised form 19 May 2007

Correspondence to: L. Zhang MD, PhD, Institute of Immunology, Medical School of Shandong University, 44 Wenhua Xi Road, Jinan Shandong 250012, China. E-mail: zhang\_lining@hotmail.com

<sup>1</sup>These two authors contributed equally to this work.

## Abstract

The engagement of the 4-1BB (CD137) co-stimulatory pathway promotes the activation and proliferation of conventional CD4<sup>+</sup> T and CD8<sup>+</sup> T cells, but the role of 4-1BB co-stimulation in CD4<sup>+</sup> CD25<sup>+</sup> regulatory T cells (Treg) is less clear. In particular, whether 4-1BB stimulation affects the expression of Foxp3, a master gene for Treg, is unknown. This study demonstrates that co-stimulation of 4-1BB engaged by an agonistic antibody promotes the proliferation of Treg in a dependent manner of low-concentration interleukin-2 *in vitro*. The 4-1BB-expanded Treg maintain Foxp3 expression and their ability to suppress conventional CD4<sup>+</sup> T cells and their feature to produce no interleukin-2. However, the 4-1BB-expanded Treg produce increased levels of interferon- $\gamma$ , whose significance is unknown. Thus, 4-1BB co-stimulation plays a role in the expansion of functional CD4<sup>+</sup> CD25<sup>+</sup> Treg cells without adversely affecting their suppressive activity.

## Introduction

4-1BB (CD137), a member of the tumour necrosis factor receptor superfamily, is expressed on several types of cells, including activated T cells [1], dendritic cells [2, 3], monocytes [4], natural killer cells [5], neutrophils [6] and osteoblasts [7]. Unlike CD28, which is important for the activation of naïve T cells, 4-1BB co-stimulates activated T cells. A number of studies have demonstrated that the interaction of 4-1BB with its natural ligand or agonistic monoclonal antibody (MoAb) plays a role in CD4<sup>+</sup> T-cell responses both *in vitro* and *in vivo* [8, 9]. The 4-1BB co-stimulatory pathway is able to stimulate both T-cell proliferation and the production of interleukin-2 (IL-2) when T-cell receptor (TCR) signals are provided simultaneously [10]. 4-1BB may preferentially co-stimulate CD8<sup>+</sup> T cells [11]. Moreover, 4-1BB-mediated signalling plays a critical role in preventing activation-induced cell death, promoting the rejection of cardiac allograft and skin transplants, increasing T-cell cytolytic potential [11], and eradicating established tumours [12]. CD4<sup>+</sup> CD25<sup>+</sup> regulatory T cells (Treg) are the most important subset of suppressor cells and play a critical role in the maintenance of immunological tolerance [13]. TCR engagement

is required for the suppressive activity of CD4<sup>+</sup> CD25<sup>+</sup> Treg; however, the role of co-stimulation in the Treg is largely unknown.

Foxp3, which encodes a transcription factor that is genetically defective in an autoimmune and inflammatory syndrome in human and mice, is specifically expressed by naturally arising CD4<sup>+</sup> Treg [14]. Foxp3 is absolutely required for the development of CD4<sup>+</sup> CD25<sup>+</sup> Treg, but the molecules and/or factors that control the expression of Foxp3 on Treg are less clear.

In this study, we find that stimulation of 4-1BB by an agonistic antibody promotes the proliferation of Treg in a dependent manner of low-concentration interleukin-2 *in vitro*. Significantly, the anti-4-1BB-expanded CD4<sup>+</sup> CD25<sup>+</sup> Treg maintain the features of Treg.

## Materials and methods

**Mice.** Female BALB/*c* mice (5–6 weeks) were used in all experiments. Mice were purchased from Shanghai SLAC Laboratory Animal Co. Ltd (Shanghai, China). Mice were bred and maintained under specific pathogen-free conditions in the animal facilities of Shandong University.

**Reagents and antibodies.** Anti-CD3 MoAb (clone 145-2C11), phycoerythrin (PE)-conjugated anti-CD25 (clone

PC61.5), fluorescein isothiocyanate (FITC)-conjugated anti-CD4 (clone GK1.5) MoAb, and FITC-conjugated anti-mouse/rat Foxp3 (clone FJK-16s) were purchased from eBiosciences (San Diego, CA, USA). A mouse CD4<sup>+</sup> CD25<sup>+</sup> T isolation Kit was obtained from Miltenyi Biotec (Auburn, CA, USA). Mouse anti-4-1BB MoAb (clone 158,321) was purchased from R&D systems. Rat IgG2a isotype control MoAb was obtained from eBiosciences. Anti-IL-2 antibody (clone S4B6) was purchased from BD Biosciences (San Jose, CA, USA).

**Cell preparation.** Murine spleens were gently minced in RPMI-1640 containing 10% fetal bovine serum (FBS) (GIBCO-BRL, Carlsbad, CA, USA). CD4<sup>+</sup> T cells were purified from spleens using a MACS Separation Column System (Miltenyi Biotec) and then CD4<sup>+</sup> CD25<sup>+</sup> T and CD4<sup>+</sup> CD25<sup>-</sup> T cells were separated using the magnetic cell separator according to the manufacturer's protocols. The CD4<sup>+</sup> CD25<sup>-</sup> T and CD4<sup>+</sup> CD25<sup>+</sup> T subpopulations were routinely 95% and 85–90% pure respectively.

**Cell proliferation.** Spleen cells were incubated with 50 µg/ml of mitomycin C at 37 °C for 20 min and washed three times with RPMI-1640 media containing 10% FBS and then used as antigen-presenting cell (APC) in proliferation assays. Purified spleen CD4<sup>+</sup> CD25<sup>-</sup> T and CD4<sup>+</sup> CD25<sup>+</sup> T cells were stimulated with 0.5 µg/ml of soluble anti-CD3 and APC in the presence of 10 µg/ml of anti-4-1BB MoAb or rat IgG. In another group, the purified cells were stimulated by 2 µg/ml of coated anti-CD3 and 10 µg/ml of soluble anti-CD28 or anti-4-1BB MoAb without APC. After 48 h, 100 µl of supernatants were collected for cytokine detection and fresh media were added. The cells were labelled with 0.5 µCi/well [<sup>3</sup>H]-thymidine for the final 16 h, and then harvested and counted in a liquid scintillation counter (model SN 6930; Shanghai Hesuo Rihuan Photoelectric Instrument Co. Ltd, Shanghai, China). The data were shown as mean counts per minute (cpm) in triplicate wells.

**Anti-IL-2 antibody blocking.** Purified spleen CD4<sup>+</sup> CD25<sup>+</sup> T cells were stimulated with 0.5 µg/ml of soluble anti-CD3, APC, and 10 µg/ml of anti-4-1BB MoAb in the presence or absence of 20 µg/ml of anti-IL-2 antibody. Cells were cultured at 37°C in 5% CO<sub>2</sub> for 72 h. The cells were labelled with 0.5 µCi/well [<sup>3</sup>H]-thymidine for the final 16 h and then harvested and counted in a liquid scintillation counter as described above.

**Co-culture of CD4<sup>+</sup> CD25<sup>+</sup> T and CD4<sup>+</sup> CD25<sup>-</sup> T cells.** Purified spleen CD4<sup>+</sup> CD25<sup>+</sup> T cells were stimulated with 0.5 µg/ml of soluble anti-CD3 and APC in the presence of anti-4-1BB or rat IgG for 72 h. The expanded CD4<sup>+</sup> CD25<sup>+</sup> T cells were then washed three times with phosphate-buffered saline (PBS). Fresh separated spleen CD4<sup>+</sup> CD25<sup>-</sup> T cells were stimulated with 0.5 µg/ml of soluble anti-CD3 and APC in the presence or absence of the 4-1BB-expanded CD4<sup>+</sup> CD25<sup>+</sup> T cells

at 37°C in 5% CO<sub>2</sub> condition for 72 h. The cells were labelled with 0.5 µCi/well [<sup>3</sup>H]-thymidine for the final 16 h and then harvested and counted in a liquid scintillation counter as described above.

**Real-time PCR.** Total cellular RNA was extracted from purified CD4<sup>+</sup> CD25<sup>+</sup> cells using Trizol reagent (Invitrogen, Carlsbad, CA, USA), and reversely transcribed to cDNA using Reverse Transcription system (Promega, Madison, WI, USA) according to the manufacturer's protocol. The expression levels of Foxp3 were measured by real-time PCR using Platinum SYBR Green qPCR Supermix UDG kit (Invitrogen). The primers used for real-time PCR are as follows: Foxp3 primers: forward 5'-CCCA GGAAAGACAGCAACCTT-3' and reverse 5'-TTCT CACAACCAGGCCACTTG-3'; cyclophilin A primers: forward 5'-AGGGTGGTGACTTTACACGC-3' and reverse 5'-ATCCAGCCATTCAGTCTTGG-3'. SYBR green qPCR was performed using the ABI PRISM 7000 Sequence Detection System (ABI, Foster City, CA, USA). The conditions comprised an initial holding at 50 °C for 2 min and a subsequent holding at 95 °C for 10 min, which was followed by a two-step PCR programme at 95 °C for 15 s and 60 °C for 60 s for 40 cycles.

**Cytokine induction and determination.** Cells were stimulated with anti-CD3 MoAb and APC in the presence or absence of anti-4-1BB MoAb for 48 h. Cell supernatants (100 µl) were collected and IL-2 and interferon-γ (IFN-γ) production was measured with ELISA kits (Jingmei Biotech Co, Ltd, China). The IL-2 detection kit has a minimum detection of 4 pg/ml and variation is less than 10%. The INF-γ detection kit has a minimum detection of 15 pg/ml and variation is less than 8.5%.

**Flow cytometry analysis.** Cells (1 × 10<sup>6</sup>) were resuspended in PBS containing 0.5% BSA (washing buffer). For the staining of surface molecule, the cells were incubated with FITC-, PE-conjugated MoAb or their negative control antibodies as indicated for 30 min on ice. After washing twice with washing buffer, intracellular staining of Foxp3 was performed using a mouse Foxp3 staining kit (eBiosciences) according to the manufacturer's instructions. Cells were analysed using the Beckman Coulter Cytomics™ FC 500 (Beckman Coulter Inc., Fullerton, CA, USA).

**Statistical analysis.** Data analysis was done using the Student's *t*-test to assess differences between the different study groups. A value of *P* < 0.05 was considered statistically significant.

## Results

### The expansion of CD4<sup>+</sup> CD25<sup>+</sup> Treg cells by agonistic anti-4-1BB antibody needs low-concentration IL-2 *in vitro*

To examine the effect of 4-1BB co-stimulation on Treg, freshly isolated CD4<sup>+</sup> CD25<sup>+</sup> Treg cells and CD4<sup>+</sup> CD25<sup>-</sup> T cells were cultured with anti-CD3


MoAb in the presence or absence of agonistic anti-4-1BB MoAb respectively. T-cell proliferation was measured by <sup>3</sup>H-TdR incorporation assay. The stimulation by anti-CD3 MoAb alone or in the presence of anti-4-1BB MoAb failed to induce CD4<sup>+</sup> CD25<sup>+</sup> T-cell proliferation (Fig. 1A). By contrast, the presence of anti-4-1BB MoAb resulted in a significant increase in CD4<sup>+</sup> CD25<sup>-</sup> T-cell proliferation, which was comparable with that in the presence of CD28 MoAb (Fig. 1A).

To determine whether the non-responsiveness of CD4<sup>+</sup> CD25<sup>+</sup> Treg cells to anti-CD3 MoAb and anti-4-1BB MoAb is due to a lack of IL-2, we examined the proliferation of Treg cells in the presence of recombinant IL-2 (rIL-2) cytokine or APC respectively. Consistent with previous findings [15], there was a significant increase in the proliferation of CD4<sup>+</sup> CD25<sup>+</sup> Treg cells stimulated by anti-CD3 MoAb and anti-4-1BB MoAb in the presence of 20 U/ml of rIL-2 (Fig. 1B). Similarly, the presence of APC also resulted in an increase in CD4<sup>+</sup> CD25<sup>+</sup> Treg cells proliferation, synchronously


stimulated by anti-CD3 and anti-4-1BB MoAb (Fig. 1C). A similar effect was observed in CD4<sup>+</sup> CD25<sup>-</sup> Treg cells stimulated by anti-4-1BB antibody. Furthermore, the proliferation of CD4<sup>+</sup> CD25<sup>+</sup> Treg stimulated by anti-4-1BB MoAb in the presence of anti-CD3 MoAb and APC could be blocked by anti-IL-2 MoAb (Fig. 1D). Thus, IL-2 is necessary for the expansion of CD4<sup>+</sup> CD25<sup>+</sup> Treg cells mediated by agonistic anti-4-1BB MoAb.

#### 4-1BB MoAb-expanded CD4<sup>+</sup> CD25<sup>+</sup> Treg cells produce less IL-2 but more IFN- $\gamma$

T-cell receptor stimulation and 4-1BB co-stimulation, independent of the CD28 co-stimulatory pathway, are capable of inducing IL-2 production in the conventional T-cell populations [10, 16]. However, it has been shown that the CD4<sup>+</sup> CD25<sup>+</sup> Treg lack IL-2 production upon TCR stimulation [15]. To determine whether 4-1BB co-stimulation induce IL-2 production in CD4<sup>+</sup> CD25<sup>+</sup> Treg, freshly purified CD4<sup>+</sup> CD25<sup>+</sup> Treg cells from



**Figure 1** Agonistic anti-4-1BB MoAb promotes the proliferation of CD4<sup>+</sup> CD25<sup>+</sup> T cells in the dependent manner of low-concentration IL-2. (A) Freshly separated CD4<sup>+</sup> CD25<sup>-</sup> T and CD4<sup>+</sup> CD25<sup>+</sup> T cells from BALB/c mice were activated with 2  $\mu$ g/ml of coated anti-CD3 MoAb in the presence or absence of 10  $\mu$ g/ml of anti-CD28 or anti-4-1BB MoAb for 72 h. (B) Freshly purified CD4<sup>+</sup> CD25<sup>-</sup> T and CD4<sup>+</sup> CD25<sup>+</sup> T cells were activated with 0.5  $\mu$ g/ml of anti-CD3 MoAb and exogenous IL-2 (20 U/ml) in the presence of 10  $\mu$ g/ml of anti-4-1BB MoAb or rat IgG2a for 72 h. (C) Freshly purified CD4<sup>+</sup> CD25<sup>-</sup> T and CD4<sup>+</sup> CD25<sup>+</sup> T cells were activated with 0.5  $\mu$ g/ml of anti-CD3 MoAb and APC in the presence of 10  $\mu$ g/ml of anti-4-1BB MoAb or rat IgG2a (control MoAb) for 72 h. (D) The proliferation of CD4<sup>+</sup> CD25<sup>+</sup> T cells stimulated by 0.5  $\mu$ g/ml of anti-CD3 MoAb, APC ( $1 \times 10^6$  cells/well) and 10  $\mu$ g/ml of anti-4-1BB MoAb was blocked by anti-IL-2 antibody (20  $\mu$ g/ml). All samples were labelled with 0.5  $\mu$ Ci [<sup>3</sup>H]-thymidine/well for the last 16 h and all conditions were performed in triplicate and reported as mean  $\pm$  SD. The shown results are representative of five independent experiments.



**Figure 2** 4-1BB-expanded CD4<sup>+</sup> CD25<sup>+</sup> Treg cells produce less IL-2 but more IFN- $\gamma$ . CD4<sup>+</sup> CD25<sup>-</sup> T and CD4<sup>+</sup> CD25<sup>+</sup> T cells were activated with 0.5  $\mu$ g/ml of anti-CD3 MoAb and APC ( $1 \times 10^6$ /well) in the presence of 10  $\mu$ g/ml of anti-4-1BB MoAb or rat IgG. After 48 h, culture supernatant was collected and levels of IL-2 (A) and IFN- $\gamma$  (B) were analysed by an ELISA. All conditions were performed in triplicate and reported as mean  $\pm$  SD. All results are representative of three independent experiments.


BALB/*c* mice were stimulated by anti-CD3 MoAb and APC in the presence of anti-4-1BB MoAb or isotype control antibody. Forty-eight hours later, the levels of IL-2 in the supernatant were analysed by enzyme-linked immunoadsorbent assay (ELISA). As shown in Fig. 2A, although co-stimulation of 4-1BB significantly induced CD4<sup>+</sup> CD25<sup>-</sup> Treg cells to secrete high levels of IL-2 cytokine, it failed to upregulate the level of IL-2 secreted by CD4<sup>+</sup> CD25<sup>+</sup> Treg. Unexpectedly, anti-4-1BB MoAb dramatically increased IFN- $\gamma$  secretion in CD4<sup>+</sup> CD25<sup>+</sup> Treg (Fig. 2B). These results indicated that the 4-1BB co-stimulatory pathway could stimulate CD4<sup>+</sup> CD25<sup>+</sup> Treg to produce more IFN- $\gamma$ , but less IL-2 cytokine.

#### 4-1BB MoAb-expanded CD4<sup>+</sup> CD25<sup>+</sup> Treg cells maintain Foxp3 expression


The transcription factor Foxp3 is associated with the development of Treg [17]. To determine whether Foxp3 is involved in the proliferate response of CD4<sup>+</sup> CD25<sup>+</sup> Treg cells to 4-1BB co-stimulation, the expression of Foxp3 in 4-1BB-expanded CD4<sup>+</sup> CD25<sup>+</sup> Treg was analysed by real-time PCR at RNA levels and by flow cytometry at protein levels. Although the expression of Foxp3 mRNA was slightly higher in anti-4-1BB-expanded CD4<sup>+</sup> CD25<sup>+</sup> Treg than that in isotype antibody-treated CD4<sup>+</sup> CD25<sup>+</sup> Treg or fresh purified CD4<sup>+</sup> CD25<sup>+</sup> Treg (Fig. 3), there was no statistical significance among the three groups ( $P > 0.05$ ). The result of Foxp3 protein expression in anti-4-1BB-expanded CD4<sup>+</sup> CD25<sup>+</sup> Treg was similar to that of gene expression. These data demonstrate that the 4-1BB co-stimulatory signal does not decrease at least the expression of Foxp3 when it leads to the expansion of CD4<sup>+</sup> CD25<sup>+</sup> Treg.

#### 4-1BB MoAb-expanded CD4<sup>+</sup> CD25<sup>+</sup> Treg cells retain the ability to suppress CD4<sup>+</sup> CD25<sup>-</sup> T cells

To determine whether the CD4<sup>+</sup> CD25<sup>+</sup> Treg cells expanded by agonistic anti-4-1BB MoAb retained suppressive activity, the expanded CD4<sup>+</sup> CD25<sup>+</sup> Treg cells were co-cultured with freshly isolated CD4<sup>+</sup> CD25<sup>-</sup> T-responder cells in the presence of anti-CD3 MoAb and APC for 72 h. The results showed that 4-1BB-expanded CD4<sup>+</sup> CD25<sup>+</sup> Treg cells as well as fresh purified or control antibody-treated Treg cells were able to suppress CD4<sup>+</sup> CD25<sup>-</sup> T-cell proliferation (Fig. 4). Thus,



**Figure 3** 4-1BB-expanded CD4<sup>+</sup> CD25<sup>+</sup> Treg cells maintain Foxp3 expression. Freshly purified CD4<sup>+</sup> CD25<sup>+</sup> T cells were activated with 0.5  $\mu$ g/ml of anti-CD3 MoAb and APC ( $1 \times 10^6$ /well) in the presence of 10  $\mu$ g/ml of anti-4-1BB MoAb or rat IgG. The levels of Foxp3 expression were analysed by real-time PCR. All conditions were performed in triplicate and reported as mean  $\pm$  SD. All results are representative of three independent experiments.



**Figure 4** 4-1BB-expanded CD4<sup>+</sup> CD25<sup>+</sup> T cells retain the ability to suppress CD4<sup>+</sup> CD25<sup>-</sup> T cells. Freshly isolated CD4<sup>+</sup> CD25<sup>-</sup> T cells were co-cultured with fresh purified or rat IgG-treated or anti-4-BB-expanded CD4<sup>+</sup> CD25<sup>+</sup> Treg cells in the presence of 0.5 µg/ml of anti-CD3 MoAb and APC stimulation for 72 h. All samples were labelled with 0.5 µCi [<sup>3</sup>H]-thymidine/well for the last 16 h. All conditions were performed in triplicate and reported as mean ± SD. All results are representative of five independent experiments.

4-1BB-expanded CD4<sup>+</sup> CD25<sup>+</sup> Treg cells retain their suppressive activity.

## Discussion

4-1BB is a molecule expressed on CD4<sup>+</sup> CD25<sup>-</sup> responder T cells as well as CD4<sup>+</sup> CD25<sup>+</sup> Treg [18, 19]. The ligation of 4-1BB has been consistently shown to enhance TCR-driven proliferation and survival of conventional responder CD4<sup>+</sup> CD25<sup>-</sup> T cells [8, 9]. However, the role of 4-1BB in CD4<sup>+</sup> CD25<sup>+</sup> Treg remains controversial. In this regard, one report showed that the stimulation of 4-1BB with its natural ligand (4-1BB-Fc) promoted Treg proliferation *in vitro* and *in vivo* [20], whereas the other indicated that anti-4-1BB MoAb failed to expand CD4<sup>+</sup> CD25<sup>+</sup> Treg [21].

In this study, we find that agonistic anti-4-1BB MoAb indeed promote CD4<sup>+</sup> CD25<sup>+</sup> Treg proliferation, which requires exogenous IL-2 cytokine. As shown in Fig. 1A–C, anti-4-1BB MoAb could not induce the proliferation of CD4<sup>+</sup> CD25<sup>+</sup> Treg in the absence of IL-2 but could do that in the presence of IL-2 or APC. Furthermore, CD4<sup>+</sup> CD25<sup>+</sup> Treg proliferation stimulated by anti-4-1BB MoAb in the presence of APC could be blocked by anti-IL-2 MoAb (Fig. 1D). As IL-2 is needed for the effect of 4-1BB co-stimulation in CD4<sup>+</sup> CD25<sup>+</sup> Treg proliferation, at least two possibilities exist for 4-1BB signalling. One would be that 4-1BB signalling interacts with the IL-2 pathway to increase the responsiveness and/or sensitivity of Treg to IL-2. The other scenario would be that 4-1BB might deliver a signal that antagonizes the negative signalling to release the 'brake'

for Treg. Secondly, 4-1BB signalling enhances IFN-γ but not IL-2 production in CD4<sup>+</sup> CD25<sup>+</sup> Treg. This finding reveals a differential pathway for IL-2 and IFN-γ production in Treg, in which 4-1BB signalling affects the latter, not the former. In recent years, many researchers have noticed that IFN-γ can have paradoxical functions, eliciting inflammatory T helper 1 (Th1)-driven immune responses in some circumstances and enabling induced Treg to control immune responses in others [22, 23]. This observation may help explain the observation that 4-1BB signalling enhances anti-tumour immunity despite its promotion of growth of Treg [24]. The molecular pathway by which 4-1BB regulates IFN-γ secretion remains to be determined. Thirdly, our data demonstrate that the 4-1BB co-stimulatory signal neither affects the expression of Foxp3 in anti-4-1BB MoAb-expanded CD4<sup>+</sup> CD25<sup>+</sup> Treg cells, nor does it cancel their suppressive activity to the CD4<sup>+</sup> CD25<sup>-</sup> T-responder cells (see Figs. 3 and 4). Thus, the stimulation of 4-1BB by an agonistic antibody promotes the proliferation of CD4<sup>+</sup> CD25<sup>+</sup> Treg in a dependent manner of low-concentration interleukin-2 *in vitro*. Significantly, the 4-1BB MoAb-expanded CD4<sup>+</sup> CD25<sup>+</sup> Treg maintain the features of Treg.

## Acknowledgments

The author thanks Dr Wanjun Chen at NIDCR for critical reading of the manuscript. This work was supported by grants from the Natural Science Foundation of China (No. 30,628,015) and "973" Program (No. 2006CB-503,803).

## References

- 1 Myers LM, Vella AT. Interfacing T-cell effector and regulatory function through CD137 (4-1BB) co-stimulation. *Trends Immunol* 2005;26:440–6.
- 2 Wilcox RA, Chapoval AI, Gorski KS *et al.* Cutting edge: expression of functional CD137 receptor by dendritic cells. *J Immunol* 2002;168:4262–7.
- 3 Lindstedt M, Johansson-Lindbom B, Borrebaeck CA. Expression of CD137 (4-1BB) on human follicular dendritic cells. *Scand J Immunol* 2003;57:305–10.
- 4 Kienzle G, von Kempis J. CD137 (ILA/4-1BB), expressed by primary human monocytes, induces monocyte activation and apoptosis of B lymphocytes. *Int Immunol* 2000;12:73–82.
- 5 Melero I, Johnston JV, Shufford WW, Mitrler RS, Chen L. NK1.1 cells express 4-1BB (CDw137) costimulatory molecule and are required for tumor immunity elicited by anti-4-1BB monoclonal antibodies. *Cell Immunol* 1998;190:167–72.
- 6 Heinisch IV, Bizer C, Volgger W, Simon HU. Functional CD137 receptors are expressed by eosinophils from patients with IgE-mediated allergic responses but not by eosinophils from patients with non-IgE-mediated eosinophilic disorders. *J Allergy Clin Immunol* 2001;108:21–8.
- 7 Saito K, Ohara N, Hotokezaka H *et al.* Infection-induced up-regulation of the costimulatory molecule 4-1BB in osteoblastic cells and

- its inhibitory effect on M-CSE/RANKL-induced *in vitro* osteoclastogenesis. *J Biol Chem* 2004;279:13555–63.
- 8 Cannons JL, Lau P, Ghumman B *et al*. 4-1BB ligand induces cell division, sustains survival, and enhances effector function of CD4 and CD8 T cells with similar efficacy. *J Immunol* 2001;167:1313–24.
  - 9 Bansal-Pakala P, Croft M. Defective T cell priming associated with aging can be rescued by signaling through 4-1BB (CD137). *J Immunol* 2002;169:5005–9.
  - 10 DeBenedette MA, Shahinian A, Mak TW, Watts TH. Costimulation of CD28<sup>-</sup> T lymphocytes by 4-1BB ligand. *J Immunol* 1997;158:551–9.
  - 11 Shuford WW, Klussman K, Trichler DD *et al*. 4-1BB costimulatory signals preferentially induce CD8<sup>+</sup> T cell proliferation and lead to the amplification *in vivo* of cytotoxic T cell responses. *J Exp Med* 1997;186:47–55.
  - 12 Keegan AD, Paul WE. Multichain immune recognition receptors: similarities in structure and signaling pathways. *Immunol Today* 1992;13:63–8.
  - 13 Singh B, Read S, Asseman C *et al*. Control of intestinal inflammation by regulatory T cells. *Immunol Rev* 2001;182:190–200.
  - 14 Schubert LA, Jeffery E, Zhang Y, Ramsdell F, Ziegler SF. Scurfin (FOXP3) acts as a repressor of transcription and regulates T cell activation. *J Biol Chem* 2001;276:37672–9.
  - 15 Piccirillo CA, Shevach EM. Naturally-occurring CD4<sup>+</sup> CD25<sup>+</sup> immunoregulatory T cells: central players in the arena of peripheral tolerance. *Semin Immunol* 2004;16:81–8.
  - 16 Saoulli K, Lee SY, Cannons JL *et al*. CD28-independent, TRAF2-dependent costimulation of resting T cells by 4-1BB ligand. *J Exp Med* 1998;187:1849–62.
  - 17 Hori S, Nomura T, Sakaguchi S. Control of regulatory T cell development by the transcription factor Foxp3. *Science* 2003;299:1057–61.
  - 18 McHugh RS, Whitters MJ, Piccirillo CA *et al*. CD4<sup>(+)</sup>CD25<sup>(+)</sup> immunoregulatory T cells: gene expression analysis reveals a functional role for the glucocorticoid-induced TNF receptor. *Immunity* 2002;16:311–23.
  - 19 Gavin MA, Clarke SR, Negrou E, Gallegos A, Rudensky A. Homeostasis and anergy of CD4<sup>(+)</sup>CD25<sup>(+)</sup> suppressor T cells *in vivo*. *Nat Immunol* 2002;3:33–41.
  - 20 Zheng G, Wang B, Chen A. The 4-1BB costimulation augments the proliferation of CD4<sup>+</sup> CD25<sup>+</sup> regulatory T cells. *J Immunol* 2004;173:2428–34.
  - 21 Choi BK, Bae JS, Choi EM *et al*. 4-1BB-dependent inhibition of immunosuppression by activated CD4<sup>+</sup> CD25<sup>+</sup> T cells. *J Leukoc Biol* 2004;75:785–91.
  - 22 Wood KJ, Sawitzki B. Interferon gamma: a crucial role in the function of induced regulatory T cells *in vivo*. *Trends Immunol* 2006;27:183–7.
  - 23 Wang Z, Hong J, Sun W *et al*. Role of IFN-gamma in induction of Foxp3 and conversion of CD4<sup>+</sup> CD25<sup>-</sup> T cells to CD4<sup>+</sup> Tregs. *J Clin Invest* 2006;116:2434–41.
  - 24 Strome SE, Martin B, Flies D *et al*. Enhanced therapeutic potential of adoptive immunotherapy by *in vitro* CD28/4-1BB costimulation of tumor-reactive T cells against a poorly immunogenic, major histocompatibility complex class I-negative A9P melanoma. *J Immunother* 2000;23:430–7.